
He Was Getting Weaker and More Confused. Could It Be His Drinking?
In the E.R., the man lay moaning quietly on the stretcher. His blood pressure was low, his heart rate was high. He could barely move his legs on his own, and when the E.R. doctor lifted each leg and let go, he couldn't hold them up. The doctors were worried something was compressing the man's spinal cord. The patient needed an M.R.I. right away.
After the test, the man was given fluids. He hadn't been eating or drinking much for the past few weeks, his wife told the nurse. The M.R.I. showed wear and tear in his neck and some narrowing of the spinal column in his lower back, but it didn't seem enough to cause this profound weakness. Even so, the neurosurgeon who reviewed the results thought they should start him on intravenous steroids to bring down any swelling that might not have been seen on the M.R.I.
That night, after his wife went home, the patient, tired and a little confused, could only provide the admitting doctor with a very basic story. His legs had started hurting a few months earlier. It began with a pins-and-needles feeling in his feet that over time moved upward. And he had terrible leg cramps. He couldn't sleep. He couldn't work. Then he couldn't walk. And now he was here.
The doctor found the rest of the history in his chart. Back in September, his primary-care doctor sent him for an M.R.I. and tested him for B12 deficiency and, because this was Connecticut, for Lyme disease. His B12 was low, so she started him on a supplement. He didn't have Lyme disease. And that M.R.I. showed some osteoarthritis and mild compression, so she sent him to a neurosurgeon. He was given oral steroids and referred for physical therapy. Neither helped.
By December, he was unable to leave the house. He fell several times. By January he was having problems with his memory. He missed appointments; didn't get ordered lab work. The patient had a long history of drinking, the doctor noted. The previous year, he was found guilty of driving under the influence and had to go to a court-ordered alcohol program. He was drinking less, he told the doctor. But still drinking. He had a drink earlier that day, he admitted. But only one.
Want all of The Times? Subscribe.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBS News
2 minutes ago
- CBS News
Baltimore organizations try to keep the momentum going with overdose prevention
Some Baltimore organizations are working around the clock to combat drug abuse while trying to prevent residents from overdosing. The Pride Center of Maryland's Harm Reduction Team was in action on Wednesday in the city's Old Gaucher neighborhood, handing out resources, including Narcan. Those getting this help say this work is sorely needed, adding it's a life-or-death situation. Every day, members of the Pride Center of Maryland's Harm Reduction Team are outside the nonprofit's resource center on Maryland Avenue. They're sitting at tables, which are filled with food, hygiene products, clothes -- as well as Narcan, fentanyl strips, and other health resources. It's free for anyone who walks by. Jerome Scott, the Pride Center's program manager of wellness, said the purpose is about visibility and to let people know they are here to help. "[Let people know] we see you, we care, and we have things for you," Scott said. "We just like to let our faces be known." But, they aren't just stationary. Scott packed a few drawstring bags with what was on the tables and walked several blocks around the neighborhood, handing them out to anyone he saw. A volunteer also handed out lunches alongside him. Scott said there are times he would leave Narcan and other resources in certain locations, even if no one is there, so it can be readily accessible if someone were to use it nearby. Scott stressed that it's important this work doesn't lose momentum. "These are our brothers, these are our sisters, our aunts, our uncles out here. So, we wanna be there for them," Scott said. Scott said the mass overdoses in the Penn North neighborhood in July show why this work can't slow down. Penn North is another neighborhood where Scott does outreach and brings resources to. Jessica Collins, who received some of the Pride Center's free resources, said she's also been in an addiction treatment center since May. She said these resources need to be more accessible to encourage addicts to get help. "It's just each individual taking that step to go forward to wanting that that person making that decision to want to get help," Collins said. When asked how much Narcan his team has on hand, Scott said they try to have at least 500. However, the team goes through its inventory often, especially in the summer months.
Yahoo
29 minutes ago
- Yahoo
FDA flags problems with two Boston Scientific heart devices tied to injuries and deaths
WASHINGTON (AP) — U.S. health regulators are warning doctors and patients about safety issues with two separate Boston Scientific heart devices recently linked to injuries and deaths. The Food and Drug Administration issued two alerts Wednesday about electrical problems tied to the company's heart-zapping defibrillator systems and a separate issue with a heart implant used to reduce stroke risk. The agency said the company's Endotak Reliance defibrillator wires can become calcified, leading to failures in delivering life-saving shocks to the heart, according to the FDA. Defibrillators are surgically placed in the upper chest, where they monitor irregular heartbeats and use electrical shocks to jolt the heart back to normal. As of July 24, Boston Scientific has reported 386 serious injuries and 16 deaths associated with this issue, the agency said. Ten of the deaths were judged to be due to the device failing to function properly, the company said in an email. Four were linked to attempts to surgically remove the devices from patients and two others were deemed unrelated to the implants. Boston Scientific's wires were distributed between 2002 and 2021 and are no longer available, the company noted in its letter to doctors. Some patients will need to have the devices replaced, though physicians should weigh the risks of the removal procedure. In a separate notice, the FDA said Boston Scientific recently updated instructions for implanting its Watchman device, which closes a portion of the heart's left atrium to reduce the risk of stroke. In a letter to physicians, the company noted that there is an increased risk of blockages in the bloodstream depending on the level of anesthesia for patients undergoing the initial implantation procedure. Watchman is an alternative to long-term treatment with blood thinners for patients at increased risk of stroke. As of July 30, the company has reported 120 serious injuries and 17 deaths related to the issue, the FDA said. A company investigation concluded that the safety issue 'is not associated with the design or manufacture of any component of the Watchman system. Heart devices, including defibrillators and other implants, are Boston Scientific's largest business, making up two-thirds of its $5 billion in revenue for the most recent quarter. Shares of Boston Scientific Corp. fell nearly 1.8 percent Wednesday to close at $102.95 in trading. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Yahoo
29 minutes ago
- Yahoo
Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
BEDFORD, Mass., August 06, 2025--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that Interim Chief Executive Officer Ian F. Smith will present at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025, at 11:30 a.m. ET. A live webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke's website at About Stoke TherapeuticsStoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Using Stoke's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke's first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke's initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke's proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit View source version on Contacts Stoke Media & Investor Contacts: Dawn KalmarChief Communications Officerdkalmar@ 781-303-8302 Doug SnowDirector, Communications & Investor RelationsIR@ 508-642-6485